Clinical trial · Observational
Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients
NCT04980352CI-TRIAL-00052930Pred-lungunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to determine the clinical effectiveness of multi-dimensional signatures in predicting response and prognosis of lung cancer patients. The study is a multi-center perspective research of treatment planning for patients with lung cancer. To characterize clinical effectiveness, the progression-free survival (PFS) and overall survival (OS) impacts of multi-dimensional signatures will be estimated.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prognosis | — | UNRESOLVED | — |
| Response | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| real world treatment by doctors | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS
- timeFrame
- through study completion, an average of 6 months
- description
- Progression-free survival
Secondary outcomes (1)
- measure
- OS
- timeFrame
- through study completion, an average of 1 year
- description
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with locally-advanced or metastasis lung cancer * Life expectancy \> 3 months Exclusion Criteria: * Age at diagnosis \<18 * refuse to enroll
References
Publications (0)
Data not yet available
No reference posted for this study.